<br />
DERMATOLOGY<br />
Review • europeanmedical-journal.com<br />
Reviews Around the Latest<br />
Treatments for Psoriasis<br />
Contents<br />
Previously published content from EMJ 3.1<br />
and EMJ Dermatology 6.1.<br />
01 SYMPOSIUM REVIEWS 2018<br />
IL-23 Inhibition in Psoriasis: Changing the Present, Shaping the Future 3<br />
From Evolution to Revolution: IL-23 in the Treatment of Psoriasis Patients 12<br />
02 POSTER REVIEWS 2018<br />
Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis 20<br />
Efficacy, Sustainability, and Patient-Reported Outcomes of Guselkumab 29<br />
to Treat Plaque Psoriasis in the Post-Approval Setting<br />
03 SYMPOSIUM REVIEWS 2017<br />
Interleukin-23 in Psoriasis: Integrating New Therapies in the Current 35<br />
Treatment Landscape<br />
From Registr<a title="EMJ Dermatology Review 2018 page 1" href="http://viewer.zmags.com/publication/3bf6d86d?page=1"> DERMATOLOGY Review • europeanmedical-journal.com </a>
<a title="EMJ Dermatology Review 2018 page 2" href="http://viewer.zmags.com/publication/3bf6d86d?page=2"> Contents Previously published content from EMJ 3</a>
<a title="EMJ Dermatology Review 2018 page 3" href="http://viewer.zmags.com/publication/3bf6d86d?page=3"> IL-23 Inhibition in Psoriasis: Changing the </a>
<a title="EMJ Dermatology Review 2018 page 4" href="http://viewer.zmags.com/publication/3bf6d86d?page=4"> provide further patient benefit, with focus on the</a>
<a title="EMJ Dermatology Review 2018 page 5" href="http://viewer.zmags.com/publication/3bf6d86d?page=5"> patients who are affected by psoriasis in d</a>
<a title="EMJ Dermatology Review 2018 page 6" href="http://viewer.zmags.com/publication/3bf6d86d?page=6"> Modern treatment options provide the </a>
<a title="EMJ Dermatology Review 2018 page 7" href="http://viewer.zmags.com/publication/3bf6d86d?page=7"> that showed significantly greater ACR 20</a>
<a title="EMJ Dermatology Review 2018 page 8" href="http://viewer.zmags.com/publication/3bf6d86d?page=8"> IL-23-mediated Th17 pathway.47 In contrast, the </a>
<a title="EMJ Dermatology Review 2018 page 9" href="http://viewer.zmags.com/publication/3bf6d86d?page=9"> Notably, at the end of the 1-year study, almost h</a>
<a title="EMJ Dermatology Review 2018 page 10" href="http://viewer.zmags.com/publication/3bf6d86d?page=10"> WATCH THE FULL SYMPOSIUM ONLINE https:/www.youtub</a>
<a title="EMJ Dermatology Review 2018 page 11" href="http://viewer.zmags.com/publication/3bf6d86d?page=11"> human/003729/WC500183129.pdf. Last accessed: 20 S</a>
<a title="EMJ Dermatology Review 2018 page 12" href="http://viewer.zmags.com/publication/3bf6d86d?page=12"> From Evolution to Revolution: IL-23 in the Treat</a>
<a title="EMJ Dermatology Review 2018 page 13" href="http://viewer.zmags.com/publication/3bf6d86d?page=13"> with a maintenance of response in patients with p</a>
<a title="EMJ Dermatology Review 2018 page 14" href="http://viewer.zmags.com/publication/3bf6d86d?page=14"> allow for the characterisation of a drug’s </a>
<a title="EMJ Dermatology Review 2018 page 15" href="http://viewer.zmags.com/publication/3bf6d86d?page=15"> by producing IL-22 for as long as 6 years</a>
<a title="EMJ Dermatology Review 2018 page 16" href="http://viewer.zmags.com/publication/3bf6d86d?page=16"> Finally, in immune surveillance, IL-12 acts </a>
<a title="EMJ Dermatology Review 2018 page 17" href="http://viewer.zmags.com/publication/3bf6d86d?page=17"> changes in the levels of various members of the </a>
<a title="EMJ Dermatology Review 2018 page 18" href="http://viewer.zmags.com/publication/3bf6d86d?page=18"> about any long-term effects on these cells,</a>
<a title="EMJ Dermatology Review 2018 page 19" href="http://viewer.zmags.com/publication/3bf6d86d?page=19"> [IL-23p19/Epstein–Barr virus-induced 3 (Ebi3)] in</a>
<a title="EMJ Dermatology Review 2018 page 20" href="http://viewer.zmags.com/publication/3bf6d86d?page=20"> Emerging Insights in the Treatment of Psoriasis </a>
<a title="EMJ Dermatology Review 2018 page 21" href="http://viewer.zmags.com/publication/3bf6d86d?page=21"> Clinical Response After Guselkumab Trea</a>
<a title="EMJ Dermatology Review 2018 page 22" href="http://viewer.zmags.com/publication/3bf6d86d?page=22"> In VOYAGE 1, 334 patients were initia</a>
<a title="EMJ Dermatology Review 2018 page 23" href="http://viewer.zmags.com/publication/3bf6d86d?page=23"> To further explore the impact of switching from a</a>
<a title="EMJ Dermatology Review 2018 page 24" href="http://viewer.zmags.com/publication/3bf6d86d?page=24"> patients in the withdrawal group had PASI 9</a>
<a title="EMJ Dermatology Review 2018 page 25" href="http://viewer.zmags.com/publication/3bf6d86d?page=25"> work.9 This poster describes the results from a r</a>
<a title="EMJ Dermatology Review 2018 page 26" href="http://viewer.zmags.com/publication/3bf6d86d?page=26"> guselkumab. Neutropenia was reported in f</a>
<a title="EMJ Dermatology Review 2018 page 27" href="http://viewer.zmags.com/publication/3bf6d86d?page=27"> Table 1: Gastrointestinal signs and symptoms amon</a>
<a title="EMJ Dermatology Review 2018 page 28" href="http://viewer.zmags.com/publication/3bf6d86d?page=28"> 4. Reich K et al. Efficacy and safety of </a>
<a title="EMJ Dermatology Review 2018 page 29" href="http://viewer.zmags.com/publication/3bf6d86d?page=29"> Efficacy, Sustainability, and Patient-Reported </a>
<a title="EMJ Dermatology Review 2018 page 30" href="http://viewer.zmags.com/publication/3bf6d86d?page=30"> Drug Survival is Superior Among Patients Treated</a>
<a title="EMJ Dermatology Review 2018 page 31" href="http://viewer.zmags.com/publication/3bf6d86d?page=31"> the association between changes in patient- </a>
<a title="EMJ Dermatology Review 2018 page 32" href="http://viewer.zmags.com/publication/3bf6d86d?page=32"> Absenteeism and presenteeism data through to </a>
<a title="EMJ Dermatology Review 2018 page 33" href="http://viewer.zmags.com/publication/3bf6d86d?page=33"> using a manually-operated, patient-controlled,</a>
<a title="EMJ Dermatology Review 2018 page 34" href="http://viewer.zmags.com/publication/3bf6d86d?page=34"> Mean SIAQ scores for ‘feeling abou</a>
<a title="EMJ Dermatology Review 2018 page 35" href="http://viewer.zmags.com/publication/3bf6d86d?page=35"> INTERLEUKIN-23 IN PSORIASIS: INTEGRATING NEW T</a>
<a title="EMJ Dermatology Review 2018 page 36" href="http://viewer.zmags.com/publication/3bf6d86d?page=36"> An Immunologic Understanding of Cytokine Pathway</a>
<a title="EMJ Dermatology Review 2018 page 37" href="http://viewer.zmags.com/publication/3bf6d86d?page=37"> Blocking different targets in the immunopathogeni</a>
<a title="EMJ Dermatology Review 2018 page 38" href="http://viewer.zmags.com/publication/3bf6d86d?page=38"> Guselkumab Adalimumab 0 10 </a>
<a title="EMJ Dermatology Review 2018 page 39" href="http://viewer.zmags.com/publication/3bf6d86d?page=39"> been reported in a Phase II trial.12 In summary, </a>
<a title="EMJ Dermatology Review 2018 page 40" href="http://viewer.zmags.com/publication/3bf6d86d?page=40"> A survey of the use of biologic therapy recently </a>
<a title="EMJ Dermatology Review 2018 page 41" href="http://viewer.zmags.com/publication/3bf6d86d?page=41"> addition to reducing the skin inflammation, it wou</a>
<a title="EMJ Dermatology Review 2018 page 42" href="http://viewer.zmags.com/publication/3bf6d86d?page=42"> ustekinumab: Evidence from real life in a lar</a>
<a title="EMJ Dermatology Review 2018 page 43" href="http://viewer.zmags.com/publication/3bf6d86d?page=43"> FROM REGISTRY DATA TO REAL-LIFE EXPERIENCES: A H</a>
<a title="EMJ Dermatology Review 2018 page 44" href="http://viewer.zmags.com/publication/3bf6d86d?page=44"> data, primary patient data collection, </a>
<a title="EMJ Dermatology Review 2018 page 45" href="http://viewer.zmags.com/publication/3bf6d86d?page=45"> DERMBIO is a registry for patients with psoriasis</a>
<a title="EMJ Dermatology Review 2018 page 46" href="http://viewer.zmags.com/publication/3bf6d86d?page=46"> from PsoBest suggest biologics to be associated w</a>
<a title="EMJ Dermatology Review 2018 page 47" href="http://viewer.zmags.com/publication/3bf6d86d?page=47"> 10 (45.4%) who received adalimumab, 4 (18.2%) who</a>
<a title="EMJ Dermatology Review 2018 page 48" href="http://viewer.zmags.com/publication/3bf6d86d?page=48"> Unmet Needs There are a number of unmet needs in </a>
<a title="EMJ Dermatology Review 2018 page 49" href="http://viewer.zmags.com/publication/3bf6d86d?page=49"> she presented with pneumonia. In elderl</a>
<a title="EMJ Dermatology Review 2018 page 50" href="http://viewer.zmags.com/publication/3bf6d86d?page=50"> 23. Vilarrasa E et al. ORBIT (Outcome and </a>
<a title="EMJ Dermatology Review 2018 page 51" href="http://viewer.zmags.com/publication/3bf6d86d?page=51"> INTERLEUKIN-23 INHIBITION AS A STRATEGY TO TREAT </a>
<a title="EMJ Dermatology Review 2018 page 52" href="http://viewer.zmags.com/publication/3bf6d86d?page=52"> Receptor Cytokines Source </a>
<a title="EMJ Dermatology Review 2018 page 53" href="http://viewer.zmags.com/publication/3bf6d86d?page=53"> recently published data showing that psorias</a>
<a title="EMJ Dermatology Review 2018 page 54" href="http://viewer.zmags.com/publication/3bf6d86d?page=54"> with the maintained activation of Th17 cells and </a>
<a title="EMJ Dermatology Review 2018 page 55" href="http://viewer.zmags.com/publication/3bf6d86d?page=55"> Table 1: Response to ustekinumab in patients with</a>
<a title="EMJ Dermatology Review 2018 page 56" href="http://viewer.zmags.com/publication/3bf6d86d?page=56"> CD. Do you have any insights into the genetics, </a>
<a title="EMJ Dermatology Review 2018 page 57" href="http://viewer.zmags.com/publication/3bf6d86d?page=57"> 32. Neurath MF et al. Antibodies to interle</a>